Porfimer Sodium

卟吩姆钠

Report date: 2024/04/24 11:54:23
NME

Base Information

Drug NamePorfimer Sodium
Drug Alias Name卟非姆钠PorfimernatriumPorfimerum natricum卟菲尔钠卟非尔钠 +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhotosensitizers
TargetsNot applicable
Therapy Area/IndicationsCNS Embryonal TumorPleural DiseasesUterine Cervical Dysplasia +[24] 
Global Approved IndicationsUterine Cervical DysplasiaBarrett EsophagusUrinary Bladder Neoplasms +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryCanada
Original Approved Date1993/01/01
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesNovelion Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer InstituteNovelion Therapeutics IncAptalis Pharma Us Inc
Inactive CompaniesUniversity College LondonPinnacle Biologics BvUniversity Of Miami +[6] 
Active IndicationsPleural DiseasesUterine Cervical DysplasiaBarrett Esophagus +[8] 
Inactive IndicationsCNS Embryonal TumorPrecancerous ConditionsNeoplasm Metastasis +[16] 

Other Information

ATC CodeL01XD01
Related LinksWikipediaDrugBankKEGG